Posts

diabetes meds and incident dementia

  Another recent article just came out on positive benefits for GLP-1 receptor agonists as well as SGLT-2 inhibitors, finding a decreased risk of Alzheimer’s disease and related dementias (see  dm GLP1 SGLT2 less dementia JamaNeuro2025  in dropbox, or  doi:10.1001/jamaneurol.2025.0353 )   Details : -- this was a target trial emulation study using electronic health record data from 2014-2023, from the OneFlorida+ Clinical Research Consortium of patients who were at least 50 years old with type II diabetes and no prior diagnosis of Alzheimer’s disease and related dementias (ADRD)     -- this database integrates longitudinal electronic health records linked with the National Death Index for multiple healthcare partners in Florida, with more than 21 million persons covering approximately 86% of Florida’s population, also extending into Georgia and Alabama -- 33,858 eligible patients were included in the GLP1 versus the other second-line glucose loweri...

semaglutide improves PAD symptoms in diabetes

Image
  A new drug company-sponsored study found that semaglutide, a GLP-1 receptor agonist, significantly improved walking capacity in patients with peripheral artery disease (PAD) and type II diabetes, in the STRIDE trial (see   PAD semaglutide helps Lancet2025  in dropbox, or doi.org/10.1016/ S0140-6736(25)00509-4)   Details : -- 792 patients were enrolled in this double-blind, randomized, placebo-controlled trial done in 112 outpatient clinical trial sites in 20 countries in North America, Asia and Europe, from 2020 to 2024 -- all participants were at least 18 years old and had both type II diabetes and peripheral artery disease (PAD), the latter characterized as having intermittent claudication but able to walk at least 200 meters, plus an ankle-brachial index of no more than 0.90 or a toe-brachial index of no more than 0.70. Patients also had to have a maximal walking distance on a flat treadmill limited to 600 meters because of claudication -- participants were rand...